An update on ketamine and its two enantiomers as rapid-acting antidepressants

Kai Zhang,Kenji Hashimoto

DOI: https://doi.org/10.1080/14737175.2019.1554434

IF: 4.287

2018-12-04

Expert Review of Neurotherapeutics

Abstract:<b>Introduction</b>: Depression is one of the most disabling diseases worldwide. Approximately one-third of depressed patients are treatment-resistant to the currently available antidepressants and there is a significant therapeutic time lag of weeks to months. There is a clear unmet need for rapid-acting and more efficacious treatments. (<i>R,S</i>)-ketamine, an old anesthetic drug, appears now to be going through a renaissance. <b>Areas covered</b>: This paper reviews recent literature describing the antidepressant effects of ketamine and its enantiomer (<i>S</i>)-ketamine in patients with major depressive disorder (MDD) and bipolar disorder (BD). Furthermore, the authors discuss the therapeutic potential of (<i>R</i>)-ketamine, another enantiomer of (<i>R,S</i>)-ketamine, and (<i>S</i>)-norketamine. <b>Expert commentary</b>: A number of clinical studies have demonstrated that (<i>R,S</i>)-ketamine has rapid-acting and sustained antidepressant activity in treatment-resistant patients with MDD, BD, and other psychiatric disorders. Off-label use of ketamine for mood disorders is proving popular in the United States. Meanwhile, preclinical data suggests that (<i>R</i>)-ketamine can exert longer-lasting antidepressant effects than (<i>S</i>)-ketamine in animal models of depression, and (<i>R</i>)-ketamine may have less detrimental side effects than (<i>R,S</i>)-ketamine and (<i>S</i>)-ketamine. Additionally, (<i>S</i>)-norketamine exhibits rapid and sustained antidepressant effects, with a potency similar to that of (<i>S</i>)-ketamine. Unlike (<i>S</i>)-ketamine, (<i>S</i>)-norketamine does not cause behavioral and biochemical abnormalities and could be a safer than (<i>S</i>)-ketamine too.

pharmacology & pharmacy,clinical neurology